Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05799118 · ClinicalTrials.gov registry record
Study of the Role of Genetic Modifiers in Hemoglobinopathies
A clinical trial of Sickle Cell Disease and Hemoglobinopathies, sponsored by Cyprus Institute of Neurology and Genetics.
- Recruiting
- Registry status
- 30,000
- Enrollment target
- 20
- Study locations
NCT05799118: Recruiting study of Sickle Cell Disease and Hemoglobinopathies, sponsored by Cyprus Institute of Neurology and Genetics.
NCT05799118 is a study of Sickle Cell Disease and Hemoglobinopathies that is actively recruiting participants, run by Cyprus Institute of Neurology and Genetics. The registered enrollment target is 30,000 participants, above the 152-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (19637% higher). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05799118, a study of Sickle Cell Disease and Hemoglobinopathies, is actively recruiting participants, sponsored by Cyprus Institute of Neurology and Genetics.
- RECRUITING
- Registry status
- 30,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Primary Outcome
Number of genetic variants (SNPs) associated with disease-specific phenotypes
Conditions Studied
Interventions
- GENETIC GWAS
Study Locations (20)
Other
- Lucrecia Paím Maternity - Luanda
- University of Buenos Aires - Buenos Aires
- University Hospitals Leuven - Leuven
- Universiti Brunei Darussalam - Brunei
- Larnaca General Hospital - Larnaca
- Limassol General Hospital - Limassol
- Archbishop Makarios III Hospital - Nicosia
- Paphos General Hospital - Paphos
- Centre Hospitalier Monkole - Kinshasa
- Rigshospitalet - Copenhagen
- Hippokrateio Hospital of Athens - Athens
- Laiko General Hospital - Athens
- National and Kapodistrian University of Athens - Athens
- General Hospital of Larissa - Larissa
- Emek Medical Centre - Afula
- University of Turin - Turin
- Ampang Hospital - Ampang
- Universiti Kebangsaan Malaysia - Bangi
- Universiti Sains Malaysia - Kota Bharu
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2027-09-30 |
What NCT05799118 shows while recruiting
NCT05799118 is an observational study that tracks outcomes without assigning an intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, above the 152-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (19637% higher).
The record links to 4 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which GWAS is the first listed.
NCT05799118 names 20 study sites across 2 states, led by Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05799118 about?
NCT05799118 is a clinical study titled "Study of the Role of Genetic Modifiers in Hemoglobinopathies". This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
What is the current status of trial NCT05799118?
This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2022-10-01. Estimated completion is 2027-09-30.
What conditions does trial NCT05799118 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Hemoglobinopathies, Thalassemia, Beta, Thalassemia Alpha.
What interventions are being tested in trial NCT05799118?
The interventions under investigation include: GWAS (GENETIC).
Who is sponsoring clinical trial NCT05799118?
This trial is sponsored by Cyprus Institute of Neurology and Genetics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05799118 being conducted?
This trial has 20 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05799118's enrollment target sits among peer trials
30,000 1st of 213 higher than 213 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI